Correspondence/References: Intraperitoneal Therapy for Ovarian Cancer

open access

Twenty-four years ago, David Alberts and I wrote a letter to the Journal of Clinical Oncology to speak in favor of studying intraperitoneal (IP) therapy.¹ Now, the editorial by Bookman and Brady² on the article by Tewari et al³ merits comments on this long-running debate......

REFERENCES

1. 1.↵
   1. Muggia FM,
   2. Alberts DS

   (1991) Intraperitoneal therapy in ovarian cancer: Time’s not up. J Clin Oncol 9:1510–1511.

   MedlineGoogle Scholar
2. 2.↵
   1. Bookman MA,
   2. Brady MF

   (2015) Intraperitoneal chemotherapy: Long-term outcomes revive a long-running debate. J Clin Oncol 33:1424–1426.

   FREE Full Text
3. 3.↵
   1. Tewari D,
   2. Java JJ,
   3. Salani R,
   4. et al.

   (2015) Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 33:1460–1466.

   Abstract/FREE Full Text
4. 4.↵
   1. Kwa M,
   2. Muggia F

   (2014) Ovarian cancer: A brief historical overview of intraperitoneal trials. Ann Surg Oncol 21:1429–1434.

   CrossRefMedlineGoogle Scholar
5. 5.↵
   1. Markman M,
   2. Bundy BN,
   3. Alberts DS,
   4. et al.

   (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007.

   Abstract/FREE Full Text
6. 6.↵
   1. Lesnock JL,
   2. Darcy KM,
   3. Tian C,
   4. et al.

   (2013) BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: A Gynecologic Oncology Group Study. Br J Cancer 108:1231–1237.

   CrossRefMedlineGoogle Scholar
7. 7.↵
   1. Kwa M,
   2. Edwards S,
   3. Downey A,
   4. et al.

   (2014) Ovarian cancer in BRCA mutation carriers: Improved outcome after intraperitoneal (IP) cisplatin. Ann Surg Oncol 21:1468–1473.

   CrossRefMedlineGoogle Scholar
8. 8.↵
   1. McGuire WP,
   2. Hoskins WJ,
   3. Brady MF,
   4. et al.

   (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 13:1589–1599.

   Abstract/FREE Full Text
9. 9.↵
   1. Muggia FM,
   2. Braly PS,
   3. Brady MF,
   4. et al.

   (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 18:106–115.

   Abstract/FREE Full Text

Related Articles

• CORRESPONDENCE: Reply to F.M. Muggia

  • Michael A. Bookman and
  • Mark F. Brady

  JCO Mar 10, 2016:884; published online on February 1, 2016;
  • [Full Text]
  • [PDF]
• CORRESPONDENCE: Reply to F.M. Muggia

  • John K. Chan and
  • Bradley J. Monk

  JCO Mar 10, 2016:882-883; published online on February 1, 2016;
  • [Full Text]
  • [PDF]

Articles citing this article

• Reply to F.M. Muggia JCO Mar 10, 2016:882-883
  • [Full Text]
  • [PDF]
• Reply to F.M. Muggia JCO Mar 10, 2016:884
  • [Full Text]
  • [PDF]